Christine Lovly

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers. Read More

Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year. Read More

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level. Read More

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer. Read More

A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease. Read More

Christine Lovly, MD, PhD, assistant professor of Medicine at Vanderbilt, has received a $200,000 grant to support promising new research on lung cancer. Read More

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC). Read More

A trio of Vanderbilt University scientists described their cutting-edge investigations of cellular dynamics and cancer treatment during last week’s Flexner Discovery Lecture. Read More

Three Vanderbilt University scientists on the forefront of research in cellular dynamics and cancer treatment will discuss their cutting-edge investigations during the next Flexner Discovery Lecture on Thursday, Sept. 21. Read More

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI). Read More

  Christine Lovly, Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt University Medical Center (VUMC), has been elected to The American Society for Clinical Investigation (ASCI). The ASCI is an elite honor society of physician-scientists. The Society, founded in 1908,… Read More

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. Read More

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been selected to testify before members of Congress about the importance of cancer research, including early training programs for individuals interested in science. Read More

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. Read More

When former Nashvillian Carol O’Hare speaks about a specific group of physicians at Vanderbilt-Ingram Cancer Center (VICC), her voice softens, and she refers to them affectionately as “my fellows.” Read More

Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been awarded a V Scholar Grant from the V Foundation for Cancer Research. Read More

Edward (Ned) Wikle recently celebrated the Christmas holidays with his wife and three young children, a celebration the Jackson, Mississippi-based endodontist, U.S. Navy veteran and cancer patient wasn’t sure he would have. Read More

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators. Read More

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways. Read More

The LUNGevity Foundation has awarded a 2014 Career Development Award for Translational Research to Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology. Read More